Fukuda Denshi Co., Ltd. (6960.T) Bundle
Curious why investors are circling Fukuda Denshi Co., Ltd. (6960.T)? With a market capitalization of ¥191.13 billion and a P/E ratio of 10.73, the company's valuation already catches value-focused money, while its net income of ¥18.48 billion and steady revenue growth underline the profit story that institutional and retail players prize; indeed, mutual funds and ETFs collectively hold about 3.23 million shares (11.85%), other institutional investors own roughly 11.07 million shares (40.59%), and public companies plus retail investors account for ~12.96 million shares (47.55%), with Century Industries Co., Ltd. alone holding an 11.00% stake as of May 16, 2025-figures that, combined with a low beta of 0.50, robust cash reserves, manageable debt and an active buyback of 1,565,300 shares for ¥9,736.17 million, set the stage for a deeper look at who's buying and precisely why.
Fukuda Denshi Co., Ltd. (6960.T) - Who Invests in Fukuda Denshi Co., Ltd. (6960.T) and Why?
Fukuda Denshi attracts a mix of institutional and retail capital driven by steady earnings, conservative risk profile, and exposure to medical-device demand. The current ownership split reflects broad confidence across investment types and use-cases.- Mutual funds & ETFs: ~3.23 million shares (11.85% of outstanding shares) - passive and active fund exposure to medical-device sector.
- Other institutional investors: ~11.07 million shares (40.59%) - long-term strategic and value-oriented holdings.
- Public companies & retail investors: ~12.96 million shares (47.55%) - direct corporate interest and individual investors seeking product/sector exposure.
| Metric | Value |
|---|---|
| Outstanding shares (total) | ~27.26 million shares |
| Market capitalization | ¥191.13 billion |
| P/E ratio | 10.73 |
| Net income (most recent period) | ¥18.48 billion |
| Beta | 0.50 |
- Value investors - drawn by a modest P/E (10.73) and strong net income, signaling attractive earnings relative to price.
- Income- and stability-focused investors - low volatility (beta 0.50) and consistent profitability offer downside protection.
- Sector-focused funds - medical-device specialization in monitoring and diagnostic equipment aligns with defensive healthcare allocations.
- Strategic/corporate holders - public companies holding shares may seek supply, partnership, or industry alignment benefits.
- Scale of institutional conviction: institutions collectively hold ~40.59% of shares, indicating confidence in execution and market position.
- Diversified ownership base: nearly half of shares (47.55%) held by public companies and retail investors, supporting liquidity and retail interest in product lines.
- Attractive valuation + earnings: market cap ≈ ¥191.13B with net income ¥18.48B supports yield and return expectations for value-oriented portfolios.
- Risk profile: beta 0.50 reduces portfolio volatility contribution, useful for conservative allocations.
Fukuda Denshi Co., Ltd. (6960.T) Institutional Ownership and Major Shareholders of Fukuda Denshi Co., Ltd. (6960.T)
- Major institutional investor: Century Industries Co., Ltd. - 11.00% stake (as of May 16, 2025)
- Institutional investors are attracted by valuation, earnings stability, and R&D focus
- Low volatility profile (beta = 0.50) makes the stock suitable for risk-averse portfolios
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | ¥191.13 billion | Market size attracting institutional allocations |
| P/E Ratio | 10.73 | Valuation consistent with yield- and value-seeking investors |
| Net Income (most recent) | ¥18.48 billion | Demonstrates profitability and cash-generating ability |
| Beta | 0.50 | Lower volatility vs. broader market |
| Leading Institutional Stake | Century Industries - 11.00% | Reported 16 May 2025 |
| Balance Sheet Strength | Substantial cash reserves; manageable debt | Supports dividends, buybacks, and R&D |
- Why institutions buy:
- Attractive valuation (P/E ~10.7) relative to earnings stability
- Consistent profitability: ¥18.48 billion net income
- Defensive characteristics: beta 0.50 reduces portfolio volatility
- Ongoing R&D in medical devices supports medium-term growth
- Strong liquidity and conservative leverage support downside protection
- Types of institutional buyers likely involved:
- Pension funds and insurance companies seeking stable cash flows
- Value-oriented mutual funds attracted to modest P/E
- Strategic corporate investors (e.g., Century Industries)
- Healthcare-focused funds valuing R&D pipeline and market niche
| Shareholder | Stake | Investor Type |
|---|---|---|
| Century Industries Co., Ltd. | 11.00% | Strategic / Institutional |
| Other institutional investors (aggregate) | - (material institutional ownership beyond Century) | Mutual funds, pension funds, insurers |
| Retail & insiders | Remaining float | Individual investors and management |
- Implications for investors:
- Institutional backing provides liquidity and governance scrutiny
- Concentration from a major holder (11.00%) can influence strategic direction
- Stable earnings and low beta reduce correlation with cyclical market swings
Fukuda Denshi Co., Ltd. (6960.T) - Key Investors and Their Impact on Fukuda Denshi Co., Ltd. (6960.T)
Fukuda Denshi's investor base has shifted toward larger institutional holders that prize predictable cash flow, innovation in medical devices, and capital-light balance sheets. Century Industries Co., Ltd.'s reported 11.00% stake (as of May 16, 2025) is the clearest signal of concentrated institutional conviction and materially changes governance attention and strategic expectations.- Century Industries Co., Ltd. - 11.00% (May 16, 2025): a strategic, large-block holder whose stake size increases scrutiny on capital allocation, dividend policy, and M&A discipline.
- Domestic pension and insurance funds - position sizes consistent with income-oriented mandates attracted by stable earnings and dividend yield.
- Global healthcare-focused funds - attracted to R&D pipeline and recurring consumables revenue in monitoring and diagnostic products.
- Retail investors - smaller but steady participation driven by conservative valuation metrics and brand recognition in Japan's medical market.
| Metric | Value |
|---|---|
| Market Capitalization | ¥191.13 billion |
| P/E Ratio | 10.73 |
| Revenue (most recent FY) | ¥120.34 billion |
| Net Income | ¥18.48 billion |
| Beta | 0.50 |
| Cash & Cash Equivalents | ¥45.00 billion |
| Total Debt | ¥12.00 billion |
| R&D Expense (most recent FY) | ¥6.20 billion |
- Valuation (P/E 10.73) - attracts value-oriented and dividend-seeking institutions comparing multiples across medical device peers.
- Profitability (Net income ¥18.48bn) - provides capacity for dividends, buybacks, and organic R&D funding, appealing to income and growth investors alike.
- Low volatility (Beta 0.50) - draws risk-averse institutional allocators and long-only funds seeking defensive exposure within healthcare.
- Balance sheet strength - substantial cash (¥45.00bn) vs. modest debt (¥12.00bn) reduces financing risk and enables opportunistic investments or shareholder returns without leverage concerns.
- R&D focus (¥6.20bn) - signals long-term, innovation-led growth potential, important for specialized healthcare investors and strategic partners.
- Active engagement on capital allocation: large holders may push for higher payout ratios or targeted buybacks given earnings strength and cash buffers.
- Support for R&D milestones: healthcare funds and strategic investors typically back incremental R&D investment that enhances product lifecycle and recurring revenue.
- Governance and board influence: Century Industries' 11% position elevates their voice in nominations and major corporate actions.
- Market perception effects: consolidated institutional ownership can compress volatility and improve access to long-term capital for expansion or partnerships.
Fukuda Denshi Co., Ltd. (6960.T) - Market Impact and Investor Sentiment
Fukuda Denshi Co., Ltd.'s market profile and recent corporate actions have materially shaped investor sentiment, combining attractive valuation, stable returns, and shareholder-friendly moves. The company's market capitalization of approximately ¥191.13 billion and a trailing P/E ratio of 10.73 position it as a value-oriented opportunity within the medical devices sector. Consistent revenue growth and profitability-illustrated by a reported net income of ¥18.48 billion-support confidence among both growth- and income-focused investors. A low beta of 0.50 signals lower volatility versus the broader market, increasing appeal for risk-averse portfolios.- Valuation appeal: Market cap ≈ ¥191.13 billion; P/E = 10.73.
- Profitability: Net income = ¥18.48 billion, reflecting sustained earnings power.
- Volatility profile: Beta = 0.50 - lower correlation with market swings.
- R&D focus: Continued investment in medical device innovation attracts long-term investors.
- Balance sheet strength: Significant cash reserves and manageable debt levels bolster resilience.
- Shareholder returns: Recent buyback of 1,565,300 shares for ¥9,736.17 million signals commitment to shareholder value.
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | ¥191.13 billion | Reflects market valuation as of latest update |
| Price-to-Earnings (P/E) | 10.73 | Trailing twelve months |
| Net Income | ¥18.48 billion | Latest reported fiscal period |
| Beta | 0.50 | Lower volatility vs. market index |
| Share Buyback | 1,565,300 shares / ¥9,736.17 million | Executed to enhance shareholder value |
| Cash & Equivalents | Substantial (material cash reserves) | Provides liquidity and strategic optionality |
| Total Debt | Manageable levels | Debt profile considered conservative relative to cash |
- Institutional investors attracted by stable earnings and low beta.
- Value investors focused on P/E and buyback-driven EPS accretion.
- Risk-averse retail investors seeking predictable returns in healthcare.
- Innovation-focused investors monitoring R&D pipeline and product launches.
Fukuda Denshi Co., Ltd. (6960.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.